Drug Trial Radar · NCT00380575
Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
Last checked: Nov 19, 2026Latest source record: May 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Aug 2000
Primary completion
Not stated
Study completion Feb 2003
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma US, Inc.
- First posted
- Sep 26, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
Conditions
- Hyponatremia
Interventions
YM087Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy outcome will be change from baseline in serum sodium over the duration of treatment. The primary safety outcome will be safety parameters (e.g., adverse events, vital signs, EGG, laboratory measurements).
Locations
47 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Mobile, Alabama
Site not named
Phoenix, Arizona
Site not named
Tuscon, Arizona
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Santa Rosa, California
Site not named
Miami, Florida
Site not named
Plantation, Florida
Site not named
Springfield, Illinois
Site not named
Indianapolis, Indiana
Site not named
Shreveport, Louisiana
Site not named
Worchester, Massachusetts
Site not named
Petoskey, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Rolla, Missouri
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
New York, New York
Site not named
Cleveland, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Columbia, South Carolina
Site not named
Sioux Falls, South Dakota
Site not named
Chattanooga, Tennessee
Site not named
Norfolk, Virginia
Site not named
Salem, Virginia
Site not named
Huntington, West Virginia
Site not named
Madison, Wisconsin
Site not named
Drummondville, Quebec, Canada
Site not named
Montreal 2 Sites, Quebec, Canada
Site not named
Ashkelon, Israel
Site not named
Beersheba, Israel
Site not named
Haifa 2 Sites, Israel
Site not named
Holon, Israel
Site not named
Jerusalem, Israel
Site not named
Rehovot, Israel
Site not named
Safed, Israel
Site not named
Tel Aviv, Israel
Site not named
Tel HaShomer, Israel
Site not named
Bloemfontein, South Africa
Site not named
Buff, South Africa
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.